Analytik Jena Sells AJ Blomesystem
Credit: Analytik Jena
Effective July 1, 2017, Analytik Jena AG has sold all of its shares in AJ Blomesystem GmbH to the GUS Group. The sale of the previously wholly owned subsidiary and provider of comprehensive laboratory software management and information systems (LIMS) results from the strategic orientation of Analytik Jena AG, which will focus on its core business of lab analysis in the future.
“We are glad to have found a strategic investor for AJ Blomesystem with the GUS Group, which is pursuing the goal of developing the LIMS business in the coming years, of investing in the company and thus of offering our employees long-term prospects,” says Ulrich Krauss, CEO of Analytik Jena AG.
AJ Blomesystem GmbH, which will operate under the new name of Blomesystem GmbH as of July 1, 2017, will be run independently under the umbrella of the GUS Group in the future. Krauss stresses that what is key here is that the GUS Group will take on all of the employees and maintain the locations in Jena and Wiehl.
The GUS Group provides corporate ERP solutions for the process and logistics industries. Since its founding in 1980, the Group has been pursuing a consistent process orientation along the entire supply chain. More than 200 employees work for the company around the globe. Of these, more than 160 work at GUS Deutschland GmbH locations in Cologne, Hamburg and Munich. The GUS Group is represented as a process specialist in all of Central Europe through companies in Switzerland and Denmark.
“By taking over the LIMS business, the GUS Group is expanding its offering of solutions both for the process industry as well as for analyzing and controlling institutes and is thus expanding its position as a process expert,” says Dirk Bingler, Managing Director of GUS Deutschland GmbH.
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Big Data From Social Media Helps Combat Prescription Drug CrisisNews
Researchers have conducted a critical review of existing literature to determine whether social media big data can be used to understand communication and behavioral patterns related to prescription drug abuse.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE